NCT05192876 is a clinical trial of Radiotherapy in Radiotherapy; Adverse Effect, sponsored by Daniel Zwahlen.

Who is sponsoring NCT05192876?

NCT05192876 is sponsored by Daniel Zwahlen.

What drugs are being tested in NCT05192876?

Interventions in NCT05192876: Radiotherapy.

What condition does NCT05192876 study?

NCT05192876 studies Radiotherapy; Adverse Effect, Radiotherapy; Complications, Quality of Life.

Is NCT05192876 still recruiting?

NCT05192876 is currently recruiting now. Last updated 21 May 2025.

Last reviewed 2025-05-21 · How we verify

NCT05192876

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Analysis of Outcomes and Adverse Events of Patients Undergoing Radiation Therapy

Recruiting now Last updated 21 May 2025

What this trial tests

trial testing Radiotherapy in Radiotherapy; Adverse Effect in 25,000 participants. Currently enrolling.

Timeline

1 January 2000

Primary endpoint
31 December 2025

31 December 2025

Quick facts

Lead sponsor	Daniel Zwahlen
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	25,000
Start date	1 January 2000
Primary completion	31 December 2025
Estimated completion	31 December 2025
Sites	1 location across Switzerland

Drugs / interventions tested

Radiotherapy — full drug profile →

Conditions studied

Radiotherapy; Adverse Effect — all drugs for Radiotherapy; Adverse Effect →
Radiotherapy; Complications — all drugs for Radiotherapy; Complications →
Quality of Life — all drugs for Quality of Life →

Sponsor

Daniel Zwahlen

Who can join

Adults 16 to 105, any sex, with Radiotherapy; Adverse Effect or Radiotherapy; Complications. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Analysis of outcomes and adverse events of patients undergoing radiation therapy. Quality control using data base of patient records 2000-2025

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Dose-Volume Histogram Parameters and Quality of Life in Patients with Prostate Cancer Treated with Surgery and High-Dose Volumetric-Intensity-Modulated Arc Therapy to the Prostate Bed.
Hanke L, Tang H, Schröder C, Windisch P, et al · · 2023 · cited 5× · PMID 37444564 · DOI 10.3390/cancers15133454
Converting between the International Prostate Symptom Score (IPSS) and the Expanded Prostate Cancer Index Composite (EPIC) urinary subscales: modeling and external validation.
Windisch P, Becker I, Tang H, Schröder C, et al · · 2024 · cited 2× · PMID 38310268 · DOI 10.1186/s12894-024-01421-y
Discontinuation of Palliative Brain Radiotherapy in Patients with Brain Metastases: A Case–Control Study
Windisch P, Lütscher J, Förster R, Zwahlen D, et al · · 2024

Verify or expand the search:

Other trials of Radiotherapy

Trials testing the same drug.

NCT07497607 — Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma · Phase 2 · not yet recruiting
NCT06813664 — ctDNA-Guided CURB for OPD mNSCLC on TKI (CURB-TKI) · Phase 2 · not yet recruiting
NCT07339774 — Traditional Chinese Medicine Preparation Alleviates Radiotherapy-induced Oral Mucositis in Head and Neck Cancer Patients · Phase 2 · recruiting
NCT07353671 — Topical Periplaneta Americana-Derived Meilian Fuxin Liquid for Radiation Dermatitis · Phase 2, PHASE3 · recruiting
NCT07245745 — Prospective Clinical Study Comparing PROMS After Adaptive or Conventional Radiotherapy in Prostate Cancer · NA · recruiting

Other recruiting trials for Radiotherapy; Adverse Effect

Currently open trials in the same condition.

NCT05994300 — Moderately Hypofractionated Adaptive Radiotherapy for Cervical Cancer · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05192876 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Daniel Zwahlen
Last refreshed: 21 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05192876.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing